131 results
8-K
APLS
Apellis Pharmaceuticals Inc
5 Jun 24
Submission of Matters to a Vote of Security Holders
4:50pm
independent registered public accounting firm for the fiscal year ending December 31, 2024. The results of the stockholders’ vote with respect
DEFA14A
APLS
Apellis Pharmaceuticals Inc
26 Apr 24
Additional proxy soliciting materials
4:08pm
of stockholders; 1.01 Paul Fonteyne 1.02 Stephanie Monaghan O'Brien 2. Ratification of the appointment of Deloitte & Touche LLP as our independent registered
S-8
9ak ued1r43ib
27 Feb 24
Registration of securities for employees
7:35am
S-8
EX-23.2
dessaxc
27 Feb 24
Registration of securities for employees
7:35am
8-K
60zpqzz 6yp1
8 Jan 24
Apellis Announces Preliminary Fourth Quarter and Full Year 2023 U.S. Net Product Revenues
9:07am
8-K
EX-1.1
j5q4sr8q025f9v6jnr3
1 Nov 23
Entry into a Material Definitive Agreement
7:59am
424B5
vw1pq hk0
1 Nov 23
Prospectus supplement for primary offering
7:51am
8-K
EX-99.1
mio7 ztl5
5 Oct 23
Apellis Announces Preliminary U.S. Net Revenues of Approximately $74 Million for SYFOVRE® (pegcetacoplan injection) in the Third Quarter of 2023
7:15am
DEFA14A
dosetrgh
21 Apr 23
Additional proxy soliciting materials
9:03am